OXN Oxonica

RNS Number:9985S
Oxonica plc
24 April 2008





24 April 2008

                                  Oxonica plc

   Oxonica arranges �3.0 million Discounted Notes facility to support working
                              capital requirements

Oxonica plc ("Oxonica" or the "Company""), a leading international nanomaterials
group, announces today that the Company has entered into a �3.0 million secured
Discounted Notes facility (the "Facility") with BlueCrest Capital Finance, L.P.
("BlueCrest Capital Finance")

The first tranche of discounted notes (the "First Tranche") with a total value
of �1.5 million were issued at closing of the Facility yesterday and the
remaining notes can be issued in a second tranche (the "Second Tranche") on or
after 1 September 2008 conditional upon the achievement of certain milestones
agreed with BlueCrest Capital Finance. The First Tranche notes were issued at a
discount to their nominal value equivalent to an interest rate of 14 per cent
per annum and are repayable over 36 months. In addition, the Company has issued
warrants to BlueCrest Capital Finance to subscribe for 569,801 shares in Oxonica
at 35.1p per share, exercisable at any time up to 23 April 2018. Warrants for a
further �100,000 worth of Oxonica shares will be granted on issue of the Second
Tranche notes at the average price per share for the 5 days prior to issue.

The proceeds of the issue will be used for general corporate purposes and to
support working capital requirements. Taking into account the proceeds from the
issue of the First Tranche notes, the Company's net cash balances currently
amount to approximately �4.3 million.

Coincident with the closing of the Facility, the Company's other secured lender,
HSBC, has agreed to certain changes in the relative priority of their security.

Dr Kevin Matthews, CEO of Oxonica said, "We are pleased that BlueCrest Capital
Finance has demonstrated its confidence in the considerable commercial
opportunities available to Oxonica through the provision of this additional
funding".

Farhaan Hassan, Managing Director of BlueCrest Capital Finance said, "We are
pleased to be able to support the development of Oxonica's exciting new
materials and products which address major markets, including diesel vehicles,
cosmetics and disease detection".

For further information, please contact:

Oxonica plc                                    01865 856 700
Kevin Matthews, Chief Executive
Richard Clarke, Finance Director

Panmure Gordon                                 0207 459 3600
Hugh Morgan
Andrew Potts

The Broadcast PR Business                      0207 812 6624
Matthew Locke





Notes to Editors

About Oxonica plc - www.oxonica.com

Oxonica (AIM: OXN.L) is one of the leading international nanomaterials groups
with products already launched into international markets and is listed in
London on the AIM market. It was spun-out from Oxford University in 1999.
Oxonica's mission is to focus on the development of innovative commercial
solutions for international markets using its expertise in the design and
application of nanomaterials. It owns a portfolio of demand driven products that
offer substantial benefits to the target markets of energy, healthcare,
materials and security.

The Group currently has four operating divisions: Oxonica Energy, Oxonica 
Healthcare, Oxonica Materials and Oxonica Security.  Oxonica has already 
launched products into international markets.  Lead products include:
                    
   *      EnviroxTM fuel borne catalyst - a nanocatalyst improving fuel economy
          and reducing emissions
   *      OptisolTM UV absorber - a revolutionary photostable UV protection 
          system  designed to optimise the performance of quality sunscreens and
          anti-premature aging products

Oxonica is also active in searching for the next generation of products and is
already engaged in developing transformational detection technologies which will
enable a new generation of ultrasensitive multiplex diagnostic tools for the
clinical diagnostic life science and security markets. In addition, Oxonica is
developing other UV absorber technologies into polymer systems and coatings,
based on similar technologies to that used in OptisolTM.

About BlueCrest Capital Finance, L.P. - www.bluecrestcapitalfinance.com

BlueCrest Capital Finance, L.P., is a US based commercial finance company,
providing debt financing solutions to development stage companies in a broad
range of industry sectors including IT, Communications, Hardware, Software,
Semi-conductor, Electronics, Energy, Medical Devices and Life Science. The team,
which has been together continuously since 1998, pursues debt transactions in
the $1 - 25 million range and has consummated approximately 900 transactions
with total commitments in excess of $1.9 billion.



                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
MSCBCGDSUGDGGIX

Oxonica (LSE:OXN)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024

Oxonica (LSE:OXN)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024